Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul B. Bolno M.B.A., M.D. | President, CEO & Director | 1.13M | -- | 1974 |
| Mr. Kyle B. Moran CFA | CFO & Principal Accounting Officer | 726.34k | -- | 1971 |
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer | 731.8k | -- | 1961 |
| Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Kate Rausch | Head of Investor Relations | -- | -- | -- |
| Ms. Linda Rockett J.D. | Senior VP & General Counsel | -- | -- | -- |
| Dr. Christopher Francis Ph.D. | Senior VP of Corporate Development & Head of Emerging Areas | 493.13k | 4.75M | 1978 |
| Ms. Daryn Lewis | Senior VP & Head of Human Resources | -- | -- | -- |
| Dr. Sridhar Vaddeboina Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls | -- | -- | -- |
| Ms. Anne-Marie Li-Kwai-Cheung | Chief Development Officer | -- | -- | -- |
Wave Life Sciences Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 266
Description
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Corporate Governance
Upcoming Events
August 1, 2024 at 12:30 PM UTC - August 5, 2024 at 12:30 PM UTC
Wave Life Sciences Ltd. Earnings Date